Eli Lilly and Company (LLY)vsProtalix Biotherapeutics Inc (PLX)
LLY
Eli Lilly and Company
$1,409.27
-0.11%
HEALTHCARE · Cap: $1.26T
PLX
Protalix Biotherapeutics Inc
$2.56
-1.16%
HEALTHCARE · Cap: $208.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 107148% more annual revenue ($86.46B vs $80.62M). LLY leads profitability with a 31.9% profit margin vs 23.5%. PLX trades at a lower P/E of 11.3x. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
PLX
Strong Buy66
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Attractively priced relative to earnings
Earnings expanding 2241.0% YoY
Every $100 of equity generates 23 in profit
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.2x book value
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : PLX
The strongest argument for PLX centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.5% and operating margin at 23.5%. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.45 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 66/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?